10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To compare the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients with newly diagnosed epilepsy.

          Related collections

          Author and article information

          Journal
          J. Neurol. Neurosurg. Psychiatr.
          Journal of neurology, neurosurgery, and psychiatry
          1468-330X
          0022-3050
          Oct 2013
          : 84
          : 10
          Affiliations
          [1 ] Department of Neurology, Paracelsus Medical University, Christian Doppler Klinik, Salzburg, Austria. e.trinka@salk.at
          Article
          jnnp-2011-300376
          10.1136/jnnp-2011-300376
          22933814
          af2d7e7f-cfff-4733-8d77-c9f681acd679
          History

          Levetiracetam,MRI,carbamazepine,clinical,epilepsy,monotherapy,neuroepidemiology,neurophysiol,surgery,valproic acid

          Comments

          Comment on this article